New Cancer Drug Zaltrap Discounted by 50%

By Curt Pesman and Mary Miller In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap.  The reason for the sharp price drop, company officials said, was “market resistance” to the initial price. Zaltrap was approved in August by the FDA for second-line treatment for metastatic…  Read More

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in an op-ed headlined “In Cancer Care, Cost Matters,” essentially challenged other cancer centers…  Read More

Ziv-Aflibercept gets FDA approval

Ziv-Aflibercept Approved as 2nd line treatment for metastatic CRC   For the first time in more than five years, the FDA has approved a new drug for certain patients who have metastatic colorectal cancer. The FDA has approved ZALTRAP® (ziv-aflibercept) to be used with FOLFIRI as a “second-line” treatment for patients with stage IV colorectal cancer whose…  Read More

Positive News for VEGF Trap in Colorectal Cancer

ZALTRAP® (aflibercept) added to survival time when given along with FOLFIRI to colorectal cancer patients who had already progressed on earlier oxaliplatin treatment. On April 26, 2011, sanofi-aventis and Regeneron Pharmaceuticals announced positive results for the Phase III VELOUR trial, which compared ZALTRAP to a placebo during FOLFIRI chemotherapy. Detailed results will be available at an…  Read More